The use of crops that are modified by the transfer of genes across species (GMOs, or “transgenics”) has provoked concerns that reverberate in the media and the academic press and have reached into the fields and lives of farmers in both rich and poor countries. The language in the Lugar-Casey “Global Food Security” draft legislation, which explicitly extends the research authorized under the Foreign Assistance Act to include work on GMOs, has touched off another round of debate. An issue that remains generally unaddressed amidst all the polemic is that what consumers and producers in rich countries may prefer is not necessarily what producers and consumers in poor countries may need (and want); there is a risk that the preferences of rich countries—transformed into science and development policies—may hinder the poor’s access to needed technologies.
While the charges and counter-charges have been flying, there has been a paucity of objective analysis of the subject, with advocates for one side or the other seizing upon individual case studies in support of their arguments. Now, IFPRI – the International Food Policy Research Institute -- has stepped into the fray with the first attempt at an objective look at the pros and cons of whether GMOs do, in fact, benefit farmers in developing countries. The IFPRI study – Measuring the Economic Impacts of Transgenic Crops in Developing Agriculture during the First Decade – limits itself exclusively to peer-reviewed studies of the impacts of transgenic crops in nonindustrialized agriculture. The questions addressed focused on the advantages (if any) of transgenic crops to farmers, the importance of GMOs (or lack thereof) to consumers, the magnitude and distribution of economic benefits of transgenic crops across an industry, and the international distribution of economic benefits from adoption and trade of transgenic crops.
On balance, the authors conclude that the balance sheet is promising for the few biotech crops (Bt cotton and maize, herbicide resistant soybeans) that have been introduced thus far in developing economies. However, they caution that the number of studies reviewed is small (only 137 met the criteria), and that the overall findings mask fairly wide variations in the individual studies. It’s noteworthy that the most promising experiences with GMOs were in those emerging economies with vibrant research institutions and strong markets. I.e., institutional capacity is an important determinant of whether GMOs do, in fact, begin to manifest the benefits that are claimed for them. This, in turn, points up the importance of long-term institutional development and helping to assure that developing countries have the capacity to make informed decisions about whether and how to employ these new and controversial technologies.
It’s normal for academic studies to conclude with a call for further research, thus guaranteeing further work for researchers. In this case, though, the admonition is appropriate. If ever a subject warranted dispassionate, objective analysis, this is one.